Nantes, France, April 23, 2026 – 7:30am CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech firm devoted to creating first-in-class therapies in immuno-oncology and immuno-inflammation, at this time introduced that topline outcomes from the TEDOVA Part 2 worldwide medical trial of Tedopi® in Ovarian Most cancers sponsored by ARCAGY-GINECO have been chosen for an oral presentation on the 2026 Annual Assembly of the American Society of Medical Oncology (ASCO) in Chicago, Illinois, United States (Might 29 – June 2, 2026).
Alexandra Leary, MD, PhD, Deputy Head of the Division of Medical Oncology at Gustave Roussy (Paris, France), oncologist specialising in gynaecological cancers, Chair of the GINECO group and Lead Investigator of the TEDOVA Part 2 medical trial of Tedopi®, will current topline outcomes from the TEDOVA trial evaluating Tedopi® as a upkeep therapy of ovarian most cancers.
“The neo-epitope-based vaccine OSE-2101 with or without pembrolizumab versus best supportive care as maintenance in platinum-sensitive recurrent ovarian cancer patients with controlled disease after platinum-based chemotherapy: The academic randomized TEDOVA/GINECO-OV244b/ENGOT-ov58 trial”
Fast Oral AbstractSession: Gynecologic Most cancers – Subtrack: Ovarian CancerAbstract 5510Room: E450May 30, 2026, 8:06-8:12am CDT (3:06-3:12pm EST)
TEDOVA is a three-arm Part 2 research evaluating Tedopi® as a upkeep therapy, alone or together with anti-PD1 immune checkpoint inhibitor Keytruda® (pembrolizumab), versus finest supportive care in 185 sufferers in platinum-sensitive recurrent ovarian most cancers with managed illness after platinum-based chemotherapy who’ve already obtained each bevacizumab and a PARP (Poly ADP-Ribose Polymerase) inhibitor. The first endpoint is the Development Free Survival (PFS) of the upkeep of Tedopi®, with a PD1 inhibitor, after platinum-based chemotherapy in relapsed ovarian most cancers. (NCT04713514).
More Read
ABOUT ARCAGY-GINECOARCAGY-GINECO (Groupe d’Investigateurs Nationwide pour l’Étude des Cancers de l’Ovaire et du sein) is a cooperative group based in 1993 and accredited by the French Nationwide Most cancers Institute (INCa). It makes a speciality of medical and translational analysis within the area of girls’s cancers (gynecologic cancers and metastatic breast most cancers). Its mission is to assist enhance survival and high quality of life for sufferers by initiating and coordinating medical trials in France and internationally. ARCAGY-GINECO contributes to the validation of scientific hypotheses by defining new requirements of therapy and disseminating these outcomes worldwide. Extra data on www.arcagy.org and our LinkedIn web page.
ABOUT ENGOTENGOT (European Community for Gynecological Oncological Trial teams) is a analysis community of the European Society of Gynecological Oncology (ESGO) and was based in 2007. At present, ENGOT contains 21 cooperative teams from 33 European nations. Go to ENGOT web site https://engot.esgo.org/ of LinkedIn web page.
Contacts
More Read
Ahead-looking statementsThis press launch accommodates specific or implied data and statements that is perhaps deemed forward-looking data and statements in respect of OSE Immunotherapeutics. They don’t represent historic information. These data and statements embody monetary projections which can be based mostly upon sure assumptions and assessments made by OSE Immunotherapeutics’ administration contemplating its expertise and its notion of historic tendencies, present financial and business circumstances, anticipated future developments and different elements they imagine to be applicable.
These forward-looking statements embody statements usually utilizing conditional and containing verbs akin to “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and phrases of comparable import. Though the OSE Immunotherapeutics administration believes that the forward-looking statements and knowledge are affordable, the OSE Immunotherapeutics’ shareholders and different buyers are cautioned that the completion of such expectations is by nature topic to varied dangers, identified or not, and uncertainties that are troublesome to foretell and usually past the management of OSE Immunotherapeutics. These dangers may trigger precise outcomes and developments to vary materially from these expressed in or implied or projected by the forward-looking statements. These dangers embody these mentioned or recognized within the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements will not be ensures of future efficiency. This press launch contains solely abstract data and must be learn with the OSE Immunotherapeutics Common Registration Doc filed with the AMF on April 30, 2025, together with the annual monetary report for the fiscal yr 2024, out there on the OSE Immunotherapeutics’ web site. Aside from as required by relevant legislation, OSE Immunotherapeutics points this press launch on the date hereof and doesn’t undertake any obligation to replace or revise the forward-looking data or statements.
EN_260423_OSE Immunotherapeutics – 2026 ASCO Summary vdef
